• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

    7.000 +0.940 (+15.51%)
    Streaming Delayed Price Updated: 12:48 PM EDT, Oct 14, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Coya Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
    From Coya Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
    Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
     
    Via Benzinga
    What's Going On With Coya Therapeutics Stock?
    Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
    Via ACCESS Newswire
    iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
    Via ACCESS Newswire
    Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    Via Get News
    Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
    Enters into Agreement with Bradley L. Radoff and Michael Torok 
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
     
    Via Benzinga
    Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
    Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events. 
    Via Benzinga
    Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
    From Coya Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
    Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.